Li Ting, Sun Xiaodong, Luo Feixiang, Song Shifei, Yu Ying, Lv Guoyue
Department of Hepatobiliary and Pancreas Surgery, The First Hospital of Jilin University, Changchun, Jilin Province, China.
Department of Hepatobiliary and Pancreas Surgery, The First Hospital of Jilin University, Changchun, Jilin Province, China.
Transplant Proc. 2020 Jul-Aug;52(6):1950-1952. doi: 10.1016/j.transproceed.2020.02.125. Epub 2020 May 19.
Thrombocytopenia is a common condition in patients undergoing liver transplantation (LT). Thrombocytopenia is prevalent in early postoperative phase, and it gradually improves after several weeks. Delayed severe thrombocytopenia occurring after the initial recovery of platelets is rare. We report a case of a patient with delayed severe thrombocytopenia 59 weeks after LT.
Our patient was a 61-year-old man who presented to our institution 59 weeks after undergoing LT. He presented for removal of a bile duct stent that was inserted 3 months prior. Tacrolimus replaced sirolimus for immunosuppression during the seventh week after transplantation due to sirolimus-induced nephrotoxicity. On admission, the patient's vital signs were normal and his physical examination was unremarkable. Laboratory parameters demonstrated that the platelet (PLT) level was significantly decreased to 18 × 10/L. PLTs reached a nadir of 3 × 10/L even after utilization of interleukin-11, thrombopoietin, and low-dose prednisone. Although rare, sirolimus toxicity was suspected. Therefore, sirolimus was gradually replaced by cyclosporin A in combination with low-dose prednisone. Subsequently, a normal PLT level was gradually recovered. This study was approved by the ethical committee of the First Hospital of Jilin University and was performed in accordance with the ethical standards of the Helsinki Congress and Istanbul Declaration.
Recurrent delayed severe thrombocytopenia is rare after LT. Sirolimus toxicity might be a reason for its occurrence if other possible factors are excluded. After diagnosis, sirolimus therapy should be discontinued and patients should be treated with an alternative immunosuppressive regimen.
血小板减少症是肝移植(LT)患者的常见病症。血小板减少症在术后早期很普遍,并在数周后逐渐改善。血小板最初恢复后出现的延迟性严重血小板减少症很少见。我们报告一例肝移植术后59周出现延迟性严重血小板减少症的患者。
我们的患者是一名61岁男性,在接受肝移植术后59周就诊于我院。他前来取出3个月前插入的胆管支架。由于西罗莫司引起的肾毒性,在移植后第7周,他改用他克莫司进行免疫抑制。入院时,患者生命体征正常,体格检查无异常。实验室检查参数显示血小板(PLT)水平显著降至18×10⁹/L。即使使用了白介素-11、血小板生成素和小剂量泼尼松,血小板仍降至最低点3×10⁹/L。尽管罕见,但怀疑是西罗莫司毒性所致。因此,西罗莫司逐渐被环孢素A联合小剂量泼尼松替代。随后,血小板水平逐渐恢复正常。本研究经吉林大学第一医院伦理委员会批准,并按照赫尔辛基大会和伊斯坦布尔宣言的伦理标准进行。
肝移植术后复发性延迟性严重血小板减少症很少见。如果排除其他可能因素,西罗莫司毒性可能是其发生的原因。诊断后,应停用西罗莫司治疗,并采用替代免疫抑制方案对患者进行治疗。